SCHEMBL15078587

SCHEMBL15078587

CC(C)[C@H](OC(N)=O)[C@@H](OC(N)=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
TP53 P04637 1/20 0.46
HTT P42858 1/20 0.46
EPHX1 P07099 1/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GLA P06280 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
ALOX12 P18054 1/20 0.36
CYP2C19 P33261 1/20 0.36
IDO1 P14902 1/20 0.35
TDO2 P48775 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15078511 0.92 LMNA (0.44) LMNATP53HTTEPHX1KMT2A
SCHEMBL15078566 0.92 LMNA (0.44) LMNATP53HTTEPHX1KMT2A
SCHEMBL15078557 0.92 LMNA (0.44) LMNATP53HTTEPHX1KMT2A
SCHEMBL15078455 0.86 LMNA (0.39) LMNATP53HTTEPHX1KMT2A
SCHEMBL15078465 0.86 LMNA (0.39) LMNATP53HTTEPHX1KMT2A
SCHEMBL15078401 0.86 LMNA (0.39) LMNATP53HTTEPHX1KMT2A
SCHEMBL15089429 0.86 LMNA (0.46) LMNATP53HTTEPHX1KMT2A
SCHEMBL14477708 0.86 LMNA (0.46) LMNATP53HTTEPHX1KMT2A
SCHEMBL3435079 0.86 LMNA (0.46) LMNATP53HTTEPHX1KMT2A
SCHEMBL3435920 0.86 LMNA (0.46) LMNATP53HTTEPHX1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9504668-B2 Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-29 US disclosed
US-9504668-B2 Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-29 US disclosed
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-01-28 US disclosed
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-01-28 US disclosed
US-9029589-B2 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-05-12 US disclosed
US-9029589-B2 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-05-12 US disclosed
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-06-27 US disclosed
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME MYLK, PDE3A, TNNC1 LMNA 1572/4885TP53 4111/4885HTT 762/4885
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME SCN1A, GABARAPL1, NAA10 LMNA 1876/4885TP53 4374/4885HTT 1790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.